CORDIS
EU research results

CORDIS

English EN
Metagenomics in Cardiometabolic Diseases

Metagenomics in Cardiometabolic Diseases

Objective

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.

METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.

We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 2 512 788

Administrative Contact

Akouavi Ekoue (Ms.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

France

EU Contribution

€ 2 649 374

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 1 151 649,80

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 900 050

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 911 396

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 699 999

VIB

Belgium

EU Contribution

€ 551 590

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 540 000

UNIVERSITAET LEIPZIG

Germany

EU Contribution

€ 715 480

DANONE RESEARCH SAS

France

EU Contribution

€ 159 400

CARGILL HAUBOURDIN SAS

France

EU Contribution

€ 19 000

CHALMERS TEKNISKA HOEGSKOLA AB

Sweden

EU Contribution

€ 550 000

INSERM - TRANSFERT SA

France

EU Contribution

€ 496 328

BIOBYTE SOLUTIONS GMBH

Germany

EU Contribution

€ 142 937,20

INST CARDIOMETABOLISME NUTRITION ICAN

France

CARGILL R&D CENTRE EUROPE

Belgium

Project information

Grant agreement ID: 305312

Status

Closed project

  • Start date

    1 November 2012

  • End date

    31 October 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 23 120 429,80

  • EU contribution

    € 11 999 992

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France